Journal article
The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
Ole S Sogaard, Mette E Graversen, Steffen Leth, Rikke Olesen, Christel R Brinkmann, Sara K Nissen, Anne Sofie Kjaer, Mariane H Schleimann, Paul W Denton, William J Hey-Cunningham, Kersten K Koelsch, Giuseppe Pantaleo, Kim Krogsgaard, Maja Sommerfelt, Remi Fromentin, Nicolas Chomont, Thomas A Rasmussen, Lars Ostergaard, Martin Tolstrup
PLoS Pathogens | PUBLIC LIBRARY SCIENCE | Published : 2015
Abstract
UNLABELLED: Pharmacologically-induced activation of replication competent proviruses from latency in the presence of antiretroviral treatment (ART) has been proposed as a step towards curing HIV-1 infection. However, until now, approaches to reverse HIV-1 latency in humans have yielded mixed results. Here, we report a proof-of-concept phase Ib/IIa trial where 6 aviremic HIV-1 infected adults received intravenous 5 mg/m2 romidepsin (Celgene) once weekly for 3 weeks while maintaining ART. Lymphocyte histone H3 acetylation, a cellular measure of the pharmacodynamic response to romidepsin, increased rapidly (maximum fold range: 3.7–7.7 relative to baseline) within the first hours following each ..
View full abstractGrants
Awarded by Research Council of Norway (GLOBVAC) program
Funding Acknowledgements
This study was funded by a grant from the Research Council of Norway (GLOBVAC) program (Nr: 235955) and Bionor Pharma ASA. The Research Council of Norway had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Bionor Pharma ASA contributed to the study design and the preparation of the manuscript.